Your browser doesn't support javascript.
loading
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
Hassan, Burhan; Akcakanat, Argun; Sangai, Takafumi; Evans, Kurt W; Adkins, Farrell; Eterovic, Agda Karina; Zhao, Hao; Chen, Ken; Chen, Huiqin; Do, Kim-Anh; Xie, Shelly M; Holder, Ashley M; Naing, Aung; Mills, Gordon B; Meric-Bernstam, Funda.
Afiliação
  • Hassan B; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Akcakanat A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sangai T; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Adkins F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Eterovic AK; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chen K; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Chen H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Do KA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Xie SM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Holder AM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Meric-Bernstam F; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Oncotarget ; 5(18): 8544-57, 2014 Sep 30.
Article em En | MEDLINE | ID: mdl-25261369
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Benzoxazóis / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Serina-Treonina Quinases TOR / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirimidinas / Benzoxazóis / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Serina-Treonina Quinases TOR / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2014 Tipo de documento: Article